Search Results

In early 2020 when the US Food and Drug Administration (FDA) issued a series of safety alerts on the risk of transmitting SARS-CoV-2 via fecal microbiota transplantation (FMT), the Cambridge-based stool bank OpenBiome was left with freezers full of processed donor stool samples that could not be released until tested for the new virus.

TATAA Biocenter, a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board.

According to Nova one advisor, the global Microbiome Therapeutics market was valued at USD 100.4 million in 2021 and it is expected to hit around USD 973.75 million by 2030 with a CAGR of 31.40% during the forecast period 2022 to 2030.

According to Precedence Research, the global microbiome therapeutics market size was estimated at around USD 84.3 million in 2021 and it is projected to hit around USD 973.86 million by 2030, growing at a CAGR of 31.24% from 2022 to 2030

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), today announced that it has paused enrollment in PRISM4, its Phase 3 clinical trial of CP101 in recurrent C. difficile infection (CDI) following receipt of a clinical hold letter from the U.S. Food and Drug Administration (FDA) on February 24, 2022, requesting additional information about Finch’s SARS-CoV-2 donor screening protocols.

The FDA asked Finch to pause enrollment for the trial on CP101 in recurrent C. difficile infection, pending details on how SARS-CoV-2 donor samples will be shipped to the vendor.

Lyfebulb, a patient-empowerment platform that bridges patients with industry to support user-driven innovation, education and connectivity, is pleased to announce the finalists for the 2022 “Addressing Unmet Needs in IBD” Innovation Challenge in collaboration with Bristol Myers Squibb.